Liraglotide, which is used to treat diabetes, has succeeded in reducing monthly migraine attacks by more than half by lowering the pressure of the brain.
The Lergloteide medicine is Nahed (Activist) of the GLP-1 peptide receptors.
Natural Bethylias-like receptors –1 -1 may offer a new treatment option for about one in 7 people around the world suffering from migraines, especially those who do not respond to current preventive drugs.
The study was conducted by researchers from the headache center at Napoli University, “Federico II”, and its results were presented at the European Academy of Neuroscience for 2025, in Helsinki, Finland, on June 21, and the Yorik Alier site was written about.
The researchers gave Liraglotide to 26 adults suffering from obesity and chronic migraines (defined as more than 15 days of headaches per month).
Patients indicated that they got rid of 11 days of headache per month, while the degrees of disability decreased in the testing of migraine disability assessment by 35 points, indicating an important improvement in work, study and social performance, and the benefit continued throughout the 3 -month monitoring period.
How do you reduce liglotide from headache attacks?
Nahati-like peptide receptors have received widespread attention, as treatment curricula for many diseases, including diabetes and cardiovascular disease. It helps to lower blood sugar levels and reduce body weight by curbing appetite and reducing energy intake.
Despite the low body mass index (weight divided on the square of height and is an indicator for body weight evaluating) slightly, this decrease had no effect on the recurrence of headaches, which enhances the hypothesis that reducing headaches was the result of reducing pressure in the skull, not weight loss.
“Most patients felt an improvement in the first two weeks, and they reported a significant improvement in the quality of their lives.”
“We believe that these drugs produce a decrease in the launch of the peptide associated with calcitonin, which is a major bodilized migraine by adjusting the pressure of the olive fluid and reducing intracranial intracranial pocket pressure.”
He added: “This would put off the control inside the skull as a completely new path and is to target drug.”
Light intestinal infectious side effects (especially nausea and constipation) appeared in 38% of the participants, but did not stop treatment.
“We also want to determine whether the other vote-likely-like peptide-1 receptors are able to provide the same comfort, and perhaps with a lower intestinal infectious side effects,” Dr. Braka said.
